Medical Devices Startups

Esopredict is a methylation-based risk-stratification test that quantifies DNA methylation of four genes (p16, RUNX3, HPP1, FBN1) combined with patient age to predict a patient's 5-year risk of progressing from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma. Offered by Castle as a companion to its TissueCypher test, it produces a risk score and risk level to help clinicians manage patients with non-dysplastic, indefinite, or low-grade Barrett's esophagus.

1 investor

PRIMACYT develops isolated liver cell models and toxicity testing services for medical device and pharmaceutical research. The company serves research institutions, universities, and industrial clients requiring preclinical safety assessment capabilities.

1 investor

Primaya Hospital is a network of 20 private hospitals in Indonesia offering comprehensive healthcare services including specialized centers for maternal/child care, cardiology, trauma, oncology, and other medical specialties, targeting the upper-middle-class segment. The hospital network operates across Java, Sumatra, Kalimantan, and Sulawesi, and is listed on the Indonesian Stock Exchange.

1 investor

Primex Pharmaceuticals owns and markets specialty anaesthetic pharmaceuticals for perioperative therapy on a global basis. The company acquires rights to established drug candidates and manages regulatory affairs and distribution without conducting internal R&D or manufacturing.

1 investor

A precision-medicine company that uses radiochemistry and molecular imaging to develop and manufacture radioisotope-based diagnostic and therapeutic drugs, focused on hard-to-treat cancers. It also pursues drug-development partnerships built on its radioisotope platform technology.

1 investor

Primrose Bio develops high-efficiency production systems for innovative and complex biologics, using advanced protein expression and enzyme engineering technologies deployed across commercially proven platforms. The company serves pharmaceutical developers and contract manufacturers in the biopharmaceutical industry.

1 investor

PrintBio manufactures 3D-printed bioresorbable surgical meshes designed for hernia repair and soft tissue support. The company serves surgeons and hospitals seeking customizable mesh solutions that combine stability and flexibility while reducing infection risk.

1 investor

Prismlab is a 3D printing company specializing in photocurable (SMS) 3D printing equipment and materials, serving industries including dental applications. The company develops and produces industrial-grade 3D printers, photosensitive resin materials, and software for digital dentistry workflows.

1 investor

ProAxsis provides biomarker analysis services and research assays for respiratory disease drug development, serving pharmaceutical, biotechnology, and academic research organizations.

1 investor

Probo Medical is a global provider of diagnostic imaging equipment and services that sells, rents, and repairs ultrasound systems, CT, MRI, X-ray, and other medical imaging devices to hospitals, imaging centers, veterinary clinics, and specialty medical practices. The company serves medical professionals across cardiology, women's health, pain management, and veterinary medicine with refurbished and new diagnostic imaging systems at competitive prices.

1 investor

Procarta Biosystems develops gene control technology to treat drug-resistant bacterial infections, including MRSA. The company was spun out from the John Innes Centre and Plant Biosciences Limited and focuses on anti-infective therapeutics for the biotech and pharmaceutical sector.

1 investor

ProciseDx develops diagnostic technology, including a point-of-care testing platform, drawing on expertise in central lab instrumentation and point-of-care devices. It serves the point-of-care diagnostics market.

1 investor

Profionics develops host-response biomarker technology for rapid detection and diagnosis of sepsis. The company serves healthcare providers and operates in the diagnostic and biotech sectors.

1 investor

Profundus develops an ophthalmic retinal camera that uses Multi Conjugate Adaptive Optics (MCAO) with multiple deformable mirrors to capture high-resolution, wide-field images of the retina. The device resolves retinal features down to a few microns and offers higher resolution and a larger field of view than conventional fundus cameras and single-conjugate adaptive optics systems.</parameter> <parameter name="founders">[]

1 investor

Progentec develops diagnostic and digital health solutions for autoimmune disease detection and treatment, including biomarker tests and remote monitoring technologies for clinicians and patients. The company focuses on improving health outcomes for the 25 million Americans living with autoimmune diseases.

1 investor

ProgenyHealth provides personalized maternity and neonatal intensive care management for health plan members, spanning prenatal care through 12 months postpartum. The company serves payers and physicians with integrated case management, NICU utilization oversight, and claims review services to improve maternal and infant health outcomes while reducing unnecessary healthcare costs.

1 investor

Progressive NEURO, Inc. develops medical devices for the treatment of ischemic stroke, including products that go beyond traditional aspiration and thrombectomy to improve first-pass efficacy and reduce distal emboli and vessel wall trauma. The company holds seven issued patents covering five different products.

1 investor

Wyss Zurich is a translational accelerator embedded within ETH Zurich and the University of Zurich, providing funding, infrastructure, technology platforms, and entrepreneurial support to early-stage projects. It focuses on regenerative medicine, robotics, and medical devices/bionics, helping move academic research toward clinical and commercial application.

1 investor

ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS). The company was created through a collaboration between nonprofit Project ALS, Medical Excellence Capital, and researchers at Columbia University to develop and commercialize therapeutic candidates including prosetin.

1 investor

Prolight Diagnostics develops the Psyros platform, a point-of-care diagnostic system designed to deliver laboratory-quality test results at the patient bedside with speed and cost-effectiveness. The company serves clinical diagnostics markets including traumatic brain injury and cardiac biomarkers.

1 investor

Prollenium is a manufacturer of aesthetic and skin health products, offering end-to-end product development and manufacturing at a single North American location. It also runs the PACE clinical education program to train aesthetic practitioners, serving practitioners, distributors, and consumers.

1 investor

Prolocor is developing diagnostic tests related to atherosclerotic cardiovascular disease and thrombotic risk, including platelet FcγRIIa-based assessment of risk in cancer patients. Its work is oriented toward clinical and medical diagnostics in the United States.

1 investor

Promamec is a Morocco-based medical devices company that distributes equipment and consumables from international brands to healthcare professionals and manufactures gauze bands, medical kits, and sterile drapes at its factory. It serves hospitals, dialysis centers, and other healthcare providers, and offers after-sales service across the medical sector.

1 investor

Promed Bioscience develops, manufactures, and supplies highly purified research and medical grade collagen extracted from animal tissue using proprietary methods. It provides collagen-based formulations, biomaterials, and devices customized for research, clinical, and cosmetic/skincare applications, sold through worldwide channels and partners.

1 investor